Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
14 05 2020
Historique:
pubmed: 25 4 2020
medline: 3 11 2020
entrez: 25 4 2020
Statut: ppublish

Résumé

In humans, bitter taste is mediated by 25 TAS2Rs. Many compounds, including certain active pharmaceutical ingredients, excipients, and nutraceuticals, impart their bitter taste (or in part) through TAS2R8 activation. However, effective TAS2R8 blockers that can either suppress or reduce the bitterness of these compounds have not been described. We are hereby reporting a series of novel 3-(pyrazol-4-yl) imidazolidine-2,4-diones as potent and selective TAS2R8 antagonists. In human sensory tests,

Identifiants

pubmed: 32330040
doi: 10.1021/acs.jmedchem.0c00388
doi:

Substances chimiques

Coffee 0
Hydantoins 0
Pyrazoles 0
Receptors, Cell Surface 0
Receptors, G-Protein-Coupled 0
TAS2R8 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4957-4977

Auteurs

Joseph R Fotsing (JR)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Vincent Darmohusodo (V)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Andrew P Patron (AP)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Brett W Ching (BW)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Thomas Brady (T)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Melissa Arellano (M)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Qing Chen (Q)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Timothy J Davis (TJ)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Hanghui Liu (H)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Guy Servant (G)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Lan Zhang (L)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Mark Williams (M)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Michael Saganich (M)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Tanya Ditschun (T)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Catherine Tachdjian (C)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Donald S Karanewsky (DS)

Firmenich SA, R&D North America, San Diego site, 4767 Nexus Centre Drive, San Diego, California 92121, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH